ANDA 72692, held by Barr. Ethinyl Estradiol; Norethindrone.
As of Nov 16, 2026, ANDA 72692 (Nortrel 0.5/35-21), held by Barr, was first approved by FDA on Feb 28, 1992, with 11 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 1992 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nortrel 0.5/35-210.035MG;0.5MG ยท tablet;oral-21 | Ethinyl Estradiol; Norethindrone | Discontinued |
| Dec 11, 2002 | Supplement 9Manufacturing | Approved | None posted |
| Dec 4, 2001 | Supplement 10Manufacturing | Approved | None posted |
| Dec 4, 2001 | Supplement 12Manufacturing | Approved | None posted |
| Aug 22, 2001 | Supplement 8Manufacturing | Approved | None posted |
| Mar 13, 2001 | Supplement 7Labeling | Approved | None posted |
| Mar 7, 2001 | Supplement 1Manufacturing | Approved | None posted |
| Mar 7, 2001 | Supplement 2Manufacturing | Approved | None posted |
| Mar 7, 2001 | Supplement 3Manufacturing | Approved | None posted |
| Mar 7, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Mar 7, 2001 | Supplement 5Labeling | Approved | None posted |
| Dec 21, 1999 | Supplement 6Manufacturing | Approved | None posted |
| Feb 28, 1992 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters